Several small molecules targeting the different domains of the IRE1 pathway are in the preclinical stages against cancer, diabetes, neurodegenerative diseases, etc. The RNase domain inhibitors of IRE1 (e.g., MKC-3946, STF-083010) contain an aromatic aldehyde group in the core and adjacent hydroxyl group. Here, ERN1 is linked to cancer.